CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Analyst Reco. Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 11/12/2024 GMT			5-day change	1st Jan Change
193.55 ^USD	-1.78%		-2.91%	-18.13%

12-04	Charles River Laboratories International, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 10:00 AM
11-26	Goldman Sachs Adjusts Price Target on Charles River Laboratories International to $220 From $240, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Price Target on Charles River Laboratories International to $220 From $240, Maintains Buy Rating	11-26	MT
Redburn Atlantic Adjusts PT on Charles River Laboratories International to $171 From $151, Maintains Sell Rating	11-25	MT
Baird Adjusts Price Target on Charles River Laboratories International to $197 From $211, Maintains Neutral Rating	11-25	MT
Analyst recommendations: Biogen, HP, Moderna, Shell...	11-18
TD Cowen Adjusts Price Target on Charles River Laboratories International to $227 From $203, Maintains Hold Rating	11-11	MT
Barrington Adjusts Price Target on Charles River Laboratories International to $212 From $194, Maintains Outperform Rating	11-08	MT
Morgan Stanley Raises Charles River Laboratories International's Price Target to $225 From $215	11-07	MT
UBS Adjusts Price Target on Charles River Laboratories International to $250 From $240, Maintains Buy Rating	11-07	MT
Baird Adjusts Charles River Laboratories International Price Target to $211 From $190, Maintains Neutral Rating	11-07	MT
JPMorgan Adjusts Charles River Laboratories International Price Target to $215 From $195, Maintains Neutral Rating	11-07	MT
Evercore ISI Adjusts Charles River Laboratories International Price Target to $225 From $190, Maintains In Line Rating	11-07	MT
Analyst recommendations: Corteva, Dollar Tree, JPMorgan, Microsoft, Palantir...	11-07
Deutsche Bank Raises Charles River Laboratories International Price Target to $250 From $235	11-06	MT
Deutsche Bank Adjusts Charles River Laboratories International Price Target to $235 From $240, Maintains Buy Rating	10-16	MT
Barclays Adjusts Price Target on Charles River Laboratories International to $205 From $210	10-15	MT
Redburn Atlantic Initiates Charles River Laboratories International at Sell With $151 Price Target	10-14	MT
JPMorgan Adjusts Charles River Laboratories International Price Target to $195 From $205, Maintains Neutral Rating	10-14	MT
Redburn Atlantic Initiates Charles River Laboratories International at Sell With $151 Price Target	10-14	MT
Goldman Sachs Adjusts Price Target on Charles River Laboratories International to $240 From $250, Maintains Buy Rating	10-08	MT
Evercore ISI Downgrades Charles River Laboratories International to In Line From Outperform, Adjusts PT to $190 From $225	10-07	MT
BofA Securities Downgrades Charles River Laboratories International to Neutral From Buy on Biopharma Concerns, Price Target is $215	10-02	MT
Citigroup Downgrades Charles River Laboratories International to Sell From Neutral, Adjusts PT to $175 From $215	10-01	MT
Baird Adjusts Charles River Laboratories International Price Target to $190 From $191	09-20	MT
Mizuho Adjusts Price Target on Charles River Laboratories International to $210 From $235, Maintains Neutral Rating	08-13	MT
TD Cowen Adjusts Price Target on Charles River Laboratories International to $203 From $228, Maintains Hold	08-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Analyst Reco.

Filters